Ladenburg Thalmann Financial Services Inc. trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 6.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 493,995 shares of the company’s stock after selling 33,383 shares during the period. Johnson & Johnson comprises about 0.7% of Ladenburg Thalmann Financial Services Inc.’s portfolio, making the stock its 24th biggest position. Ladenburg Thalmann Financial Services Inc.’s holdings in Johnson & Johnson were worth $64,322,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in JNJ. BlackRock Inc. increased its stake in Johnson & Johnson by 2.6% in the second quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock valued at $23,028,219,000 after purchasing an additional 4,332,612 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Johnson & Johnson by 717.9% in the second quarter. Janus Henderson Group PLC now owns 3,748,008 shares of the company’s stock valued at $495,837,000 after acquiring an additional 3,289,763 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Johnson & Johnson by 1.5% in the second quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock valued at $26,517,661,000 after acquiring an additional 3,023,110 shares during the period. Parametric Portfolio Associates LLC boosted its holdings in shares of Johnson & Johnson by 47.9% in the second quarter. Parametric Portfolio Associates LLC now owns 7,970,670 shares of the company’s stock valued at $1,054,433,000 after acquiring an additional 2,581,562 shares during the period. Finally, Stifel Financial Corp boosted its holdings in shares of Johnson & Johnson by 6,715.9% in the third quarter. Stifel Financial Corp now owns 2,572,663 shares of the company’s stock valued at $334,777,000 after acquiring an additional 2,534,918 shares during the period. Hedge funds and other institutional investors own 67.35% of the company’s stock.
In other Johnson & Johnson news, VP Paulus Stoffels sold 155,342 shares of the firm’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total value of $20,172,712.12. Following the completion of the sale, the vice president now owns 357,906 shares of the company’s stock, valued at $46,477,673.16. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.19% of the stock is currently owned by company insiders.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.72 by $0.02. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. The firm had revenue of $20.20 billion during the quarter, compared to the consensus estimate of $20.08 billion. During the same period last year, the company earned $1.58 earnings per share. The company’s revenue for the quarter was up 11.5% on a year-over-year basis. analysts anticipate that Johnson & Johnson will post 8.11 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th were issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 2.50%. The ex-dividend date was Monday, February 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 61.88%.
Several equities research analysts have recently weighed in on the company. Wells Fargo & Co reissued an “outperform” rating and issued a $160.00 price objective (up from $155.00) on shares of Johnson & Johnson in a report on Friday, January 12th. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 price objective for the company in a report on Thursday, January 11th. Credit Suisse Group set a $154.00 price objective on Johnson & Johnson and gave the company a “hold” rating in a report on Monday, January 22nd. Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, January 9th. Finally, Stifel Nicolaus increased their price objective on Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a report on Wednesday, January 24th. Four equities research analysts have rated the stock with a sell rating, nine have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $146.26.
WARNING: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2018/03/14/ladenburg-thalmann-financial-services-inc-sells-33383-shares-of-johnson-johnson-jnj.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.